Androgen deprivation therapy in the treatment of advanced prostate cancer.
- 1 January 2007
- journal article
- Vol. 9, S3-8
Abstract
This article reviews the issues and controversies relevant to the treatment of advanced prostate cancer with androgen deprivation therapy. Initially, diethylstilbestrol was used for achieving androgen deprivation, but was replaced by luteinizing hormone-releasing hormone (LHRH). Adverse events associated with LHRH agonists include the flare phenomenon, hot flashes, loss of libido, erectile dysfunction, depression, muscle wasting, anemia, and osteoporosis. Intermittent therapy has been advocated to reduce morbidity of treatment. The addition of an antiandrogen provides maximum androgen blockade. There remains controversy regarding the timing of the addition of an antiandrogen. Secondary hormonal therapies include antiandrogens, adrenal androgen inhibitors, and estrogens.Keywords
This publication has 38 references indexed in Scilit:
- Recent progress in hormonal therapy for advanced prostate cancerCurrent Opinion in Urology, 2006
- Should Intermittent Androgen Deprivation Be Used in Routine Clinical Practice?Journal of Clinical Oncology, 2005
- A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomyInternational Journal of Radiation Oncology*Biology*Physics, 2004
- Management of Bone Loss in Men With Prostate CancerJournal of Urology, 2003
- Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group.2000
- Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot studyUrology, 1996
- Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.Journal of Clinical Oncology, 1993
- Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies.1988
- Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer.BMJ, 1985
- BIPHASIC REGULATION OF THE GONADOTROPIN-RELEASING HORMONE RECEPTOR BY RECEPTOR MICROAGGREGATION AND INTRACELLULAR CA2+ LEVELS1984